THYROID CARCINOMA-ASSOCIATED GENETIC MUTATIONS ALSO OCCUR IN THYROID LYMPHOMAS

[1]  A. Dobrovic,et al.  Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders , 2012, Haematologica.

[2]  L. Medeiros,et al.  N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas , 2012, Modern Pathology.

[3]  R. Foà,et al.  Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. , 2012, Blood.

[4]  G. Follows,et al.  High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies , 2011, British journal of haematology.

[5]  Rajni Sharma,et al.  PAX8 immunostaining of anaplastic thyroid carcinoma: a reliable means of discerning thyroid origin for undifferentiated tumors of the head and neck. , 2011, Human pathology.

[6]  K. Kinzler,et al.  Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia , 2011, Leukemia.

[7]  S. Pileri,et al.  BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[8]  Y. Nikiforov.  Molecular diagnostics of thyroid tumors. , 2011, Archives of pathology & laboratory medicine.

[9]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[10]  C. Klemke,et al.  High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. , 2011, Blood.

[11]  W. Hahn,et al.  Recurrent BRAF mutations in Langerhans cell histiocytosis. , 2010, Blood.

[12]  A. Klimkowska,et al.  BRAF mutations in sporadic colorectal carcinoma from polish patients. , 2010, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[13]  F. Pacini,et al.  Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. , 2010, The Journal of clinical endocrinology and metabolism.

[14]  R. Seethala,et al.  Contribution of molecular testing to thyroid fine‐needle aspiration cytology of “follicular lesion of undetermined significance/atypia of undetermined significance” , 2010, Cancer cytopathology.

[15]  Yuri E Nikiforov,et al.  Molecular diagnostics and predictors in thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[16]  P. Gaulard,et al.  The mechanisms underlying MMR deficiency in immunodeficiency‐related non‐Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms , 2009, International journal of cancer.

[17]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[18]  M. Nikiforova,et al.  Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. , 2009, The Journal of clinical endocrinology and metabolism.

[19]  D. Elder,et al.  CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations , 2009, Oncogene.

[20]  A. El‐Naggar,et al.  Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer , 2007, Clinical Cancer Research.

[21]  C. Der,et al.  Signaling Interplay in Ras Superfamily Function , 2005, Current Biology.

[22]  M. Xing,et al.  BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.

[23]  S. Swerdlow,et al.  Utility of routine classical cytogenetic studies in the evaluation of suspected lymphomas: results of 279 consecutive lymph node/extranodal tissue biopsies. , 2004, American journal of clinical pathology.

[24]  D. Clark,et al.  Mutational Analysis of BRAF in Fine Needle Aspiration Biopsies of the Thyroid: A Potential Application for the Preoperative Assessment of Thyroid Nodules , 2004, Clinical Cancer Research.

[25]  H. S. Kim,et al.  BRAF mutations in non-Hodgkin's lymphoma , 2003, British Journal of Cancer.

[26]  M. Nikiforova,et al.  BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.

[27]  A. Fischer,et al.  Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. , 2003, American journal of clinical pathology.

[28]  P. Ladenson,et al.  BRAF mutation in papillary thyroid carcinoma. , 2003, Journal of the National Cancer Institute.

[29]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[30]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[31]  D Puthier,et al.  High incidence of N and K‐Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis , 2001, Human mutation.

[32]  T. Habermann,et al.  Primary thyroid lymphoma. , 1999, Seminars in oncology.

[33]  I. Fleming,et al.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985‐1995 , 1998, Cancer.

[34]  N. T. Pedersen,et al.  Primary non‐Hodgkin's lymphoma of the thyroid gland: a population based study , 1996, Histopathology.

[35]  M. Boccadoro,et al.  N- and K-ras oncogenes in plasma cell dyscrasias. , 1994, Leukemia & lymphoma.

[36]  S. Rubin,et al.  Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. , 1990, Molecular endocrinology.

[37]  M. Bar‐eli,et al.  The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. , 1990, Blood.

[38]  B. Caillou,et al.  Presence of mutations in all three ras genes in human thyroid tumors. , 1990, Oncogene.

[39]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[40]  N. Lemoine,et al.  High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. , 1989, Oncogene.

[41]  Daan Brandenbarg.  The National. , 1892 .

[42]  Mario Cazzola,et al.  The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. , 2012, Blood.

[43]  Janice Patterson,et al.  High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast , 2010, Modern Pathology.

[44]  F. Huang,et al.  Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro , 2009, International journal of cancer.

[45]  B. Sander,et al.  Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia , 2005, Leukemia.

[46]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.